ATXI

Avenue Therapeutics Inc. (ATXI) | Rumor.io

Avenue Therapeutics

ATXI

Attention (50-day avg)0%

Attention rank (50-day avg)#4,234

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.38

Market capitalization1.6M

Earnings per share-0.86

Dividend yield (TTM)—

Revenue (annual)1.4M

Net income (annual)-2.9M

Social

What share of all stock conversation is about ATXI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jan 24

$ATXI is expected to retest $2 next week.
The stock's gap is being filled, with some anticipating good news to be released at this low float and high volume.
A price target of $5 is mentioned, with a float of 9.9M and short float of 1.3%.

Generated by AI

Sentiment

Of the messages about ATXI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.04% +20.91
Bearish	—	—	—	0.96% -20.91

Bullish· Jan 24

The low float of $ATXI, with only 1.5 million shares outstanding, is expected to lead to significant price appreciation.
$ATXI has a high short-term price target of $8, driven by the stock's potential to break through key resistance levels.
The company's extension until April 25, 2025, may lead to positive news and further drive the stock's upward momentum.

Bearish· Jan 24

$ATXI may retest $2 next week after a potential retest.
$ATXI's price action suggests a pump and dump scenario, with shorts covering and a potential break to $1.80.
$ATXI's recent price drop from $3.19 to $1.68 is seen as unsustainable, with some investors labeling it a "premarket pump and dump scam".

Generated by AI

Topics

Of the messages about ATXI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	100%	15.03%
Analysts	0%	0%	0%	0%
Announcements	0%	0%	0%	55.56%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	29.41%

Announcements· Jan 4

Avenue Therapeutics, Inc. ($ATXI) has reached a final agreement with the U.S. FDA for the Phase 3 safety study for IV Tramadol.
The company plans to initiate the Phase 3 safety study as soon as possible, subject to obtaining necessary financing through a strategic partnership.
$ATXI shares have experienced significant price increases, up 67% after the FDA agreement and 52% pre-market, with a 84% sentiment boost on the news.

Technical Analysis· Jan 4

$ATXI is expected to experience a massive short opportunity due to its past chart history of not holding gains.
The stock appears to be forming a bullflag and a handle, with potential targets of $0.50-$0.75 and $0.36.
The RSI is hot and the volume is sketchy, with some traders waiting for a break above $0.40 and others expecting a bounce or a return to VWAP.

Generated by AI

Community

Of the messages about ATXI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	3.72%
Newcomers	100%	100%	100%	96.28%

Regulars· Jan 5

Avenue Therapeutics has reached a final agreement with the FDA on the Phase 3 safety study protocol and statistical analysis approach for intravenous tramadol.
The company has secured $5 million in proceeds through a warrant exercise to fuel its neurologic disease therapies.
$ATXI is experiencing high volume, which may be a sign of a squeeze, with a float rotation count of 2 and a gain of 16.0% so far.

Newcomers· Jan 5

Newcomers are focusing on Avenue Therapeutics' ($ATXI) recent market activity, with some observing a dip in stock price following a high-volume day.
The exercise of warrants by accredited investors is being discussed, which will add 16.5 million shares to the outstanding stock and generate near $5.0 million in gross proceeds for the company.
Some traders are predicting a potential bounce for $ATXI, citing a strong support zone at $0.25-$0.27 and a possible test of the $0.33-$0.35 level.

Generated by AI

Also Discussed

Investors talking about ATXI also mention

#	Name	Attention
1	Fortress Biotech, Inc.FBIO	0%0
2	Kiora Pharmaceuticals Inc.KPRX	0%0
3	NRBO - NeuroBo Pharmaceuticals, Inc.	——
4	PEGY - Pineapple Energy Inc.	——
5	FWBI - First Wave BioPharma, Inc.	——
6	MGAM - Mobile Global Esports Inc.	——
7	PaxMedica Inc.PXMD	0%0
8	Journey Medical Corp. Common StockDERM	0%0
9	PBLA - Panbela Therapeutics, Inc.	——
10	Intelligent Living Application Group Inc.ILAG	0%new

Avenue Therapeutics Inc.

Healthcare
Biotechnology

Avenue Therapeutics is a specialty pharmaceutical company focused on developing and commercializing therapies for treating neurologic diseases. The company is headquartered in Bay Harbor Islands, Florida and operates as a subsidiary of Fortress Biotech. Avenue Therapeutics pursues a focused pipeline of product candidates designed to address serious neurological conditions. These include AJ201, currently in clinical development for spinal and bulbar muscular atrophy, intravenous tramadol for post-operative acute pain management as a potential alternative to conventional opioids in intensive care settings, and BAER-101 for epilepsy and panic disorders. The company's strategy centers on acquiring, licensing, and commercializing pharmaceutical products tailored for hospital intensive care environments. By focusing on underserved neurological and rare disease indications, Avenue Therapeutics aims to provide therapeutic options that address unmet medical needs in specialized treatment settings.

Website

Location

1111 Kane Concourse

Bay Harbor Islands, FL, 33154

United States

Social

What share of all stock conversation is about ATXI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jan 24

$ATXI is expected to retest $2 next week.
The stock's gap is being filled, with some anticipating good news to be released at this low float and high volume.
A price target of $5 is mentioned, with a float of 9.9M and short float of 1.3%.

Generated by AI

Sentiment

Of the messages about ATXI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	99.04% +20.91
Bearish	—	—	—	0.96% -20.91

Bullish· Jan 24

The low float of $ATXI, with only 1.5 million shares outstanding, is expected to lead to significant price appreciation.
$ATXI has a high short-term price target of $8, driven by the stock's potential to break through key resistance levels.
The company's extension until April 25, 2025, may lead to positive news and further drive the stock's upward momentum.

Bearish· Jan 24

$ATXI may retest $2 next week after a potential retest.
$ATXI's price action suggests a pump and dump scenario, with shorts covering and a potential break to $1.80.
$ATXI's recent price drop from $3.19 to $1.68 is seen as unsustainable, with some investors labeling it a "premarket pump and dump scam".

Generated by AI

Topics

Of the messages about ATXI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	100%	15.03%
Analysts	0%	0%	0%	0%
Announcements	0%	0%	0%	55.56%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	29.41%

Announcements· Jan 4

Avenue Therapeutics, Inc. ($ATXI) has reached a final agreement with the U.S. FDA for the Phase 3 safety study for IV Tramadol.
The company plans to initiate the Phase 3 safety study as soon as possible, subject to obtaining necessary financing through a strategic partnership.
$ATXI shares have experienced significant price increases, up 67% after the FDA agreement and 52% pre-market, with a 84% sentiment boost on the news.

Technical Analysis· Jan 4

$ATXI is expected to experience a massive short opportunity due to its past chart history of not holding gains.
The stock appears to be forming a bullflag and a handle, with potential targets of $0.50-$0.75 and $0.36.
The RSI is hot and the volume is sketchy, with some traders waiting for a break above $0.40 and others expecting a bounce or a return to VWAP.

Generated by AI

Community

Of the messages about ATXI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	3.72%
Newcomers	100%	100%	100%	96.28%

Regulars· Jan 5

Avenue Therapeutics has reached a final agreement with the FDA on the Phase 3 safety study protocol and statistical analysis approach for intravenous tramadol.
The company has secured $5 million in proceeds through a warrant exercise to fuel its neurologic disease therapies.
$ATXI is experiencing high volume, which may be a sign of a squeeze, with a float rotation count of 2 and a gain of 16.0% so far.

Newcomers· Jan 5

Newcomers are focusing on Avenue Therapeutics' ($ATXI) recent market activity, with some observing a dip in stock price following a high-volume day.
The exercise of warrants by accredited investors is being discussed, which will add 16.5 million shares to the outstanding stock and generate near $5.0 million in gross proceeds for the company.
Some traders are predicting a potential bounce for $ATXI, citing a strong support zone at $0.25-$0.27 and a possible test of the $0.33-$0.35 level.

Generated by AI

Avenue Therapeutics

Social

Jan 24

Sentiment

Bullish· Jan 24

Bearish· Jan 24

Topics

Announcements· Jan 4

Technical Analysis· Jan 4

Community

Regulars· Jan 5

Newcomers· Jan 5

Also Discussed

Avenue Therapeutics Inc.

Company Information

Location

Also Discussed

Social

Jan 24

Sentiment

Bullish· Jan 24

Bearish· Jan 24

Topics

Announcements· Jan 4

Technical Analysis· Jan 4

Community

Regulars· Jan 5

Newcomers· Jan 5